Clinical Diagnosis & Product Solutions

Aberrant glycosylation disrupts normal cellular functions and contributes to tumorigenesis through modified glycan expression and glycosyltransferase mutations, thereby promoting cancer progression. AFP-L3 is a glycosylated variant of AFP, predominantly found in liver cancer patients, and its ratio to total AFP improves diagnostic specificity. Hotgen’s independently developed fully automated AFP-L3 affinity capture assay is non-invasive and highly accessible. It demonstrates superior sensitivity and specificity in differentiating benign from malignant lesions—particularly in patients with AFP-negative or low-AFP hepatocellular carcinoma, where it significantly enhances the detection rate of early-stage liver cancer.